Blood pressure, forearm arterial hemodynamics (with a pulsed Doppler flowmeter), and echocardiographic parameters were studied in 16 patients with sustained essential hypertension before and 3 months after administration of the converting enzyme inhibitor perindopril. In a single-blind study versus placebo, it was shown that perindopril significantly reduced blood pressure (p<O.Ol), whereas there was an increase in brachial blood flow (p<O.O1) because of a simultaneous increase in blood flow velocity (p<O.Ol) and arterial diameter (p<O.O1). During a 5-minute period of wrist occlusion, blood flow velocity was reduced to a greater extent with perindopril than with placebo (p<O.OOl), whereas corresponding reductions in arterial diameter were equivalent, indicating that the increase in diameter after perindopril could not be explained simply on the basis of flow-dependent dilatation. During active treatment, brachial artery compliance increased (p<0.01) and pulse wave velocity decreased (p<0.01), whereas there was no change in the tangential tension of the arterial wall, defined as the product of mean arterial pressure and arterial diameter. Four weeks after treatment was stopped, blood pressure and forearm arterial hemodynamics returned toward baseline values. Cardiac mass was significantly decreased after perindopril (p<0.01) and remained decreased 4 weeks after cessation of treatment. The study showed that the arterial modifications caused by perindopril, (i.e., an increase in arterial diameter and compliance) were largely unrelated to blood pressure reduction and involved a drug-related relaxation of arterial smooth muscle and that a differential response in cardiac and arterial changes occurred after the treatment was stopped. (Circulation 1988;78:941-950 
Patients and Methods Patients
Sixteen patients with sustained hypertension (12 men and four women) were included in the study. Age range was between 24 and 61 years (mean, 49 years). Mean body weight and body surface area were respectively 71+2 kg and 1.83+0.03 m2 (+SEM). In all patients, previous treatments, including diuretics or (3-blocking agents or both, were discontinued at least 4 weeks before the study. In all 16 subjects, diastolic pressure remained above 100 mm Hg throughout this ambulatory washout period. Patients had no signs, symptoms, or history of cardiac or renal failure, coronary insufficiency, or major diseases other than hypertension. The cardiothoracic ratio on chest x-ray was within the normal range. On the basis of previously described7,9 thorough investigations, all patients were considered to have essential hypertension. Informed consent was obtained from each patient after a detailed description of the procedure. The protocol was approved by INSERM (Institut National de la Sante et de la Recherche Medicale).
Study Design
Of the 18 patients recruited during the washout period, two were found to be placebo-responders after 4 weeks of follow-up. Thie 16 remaining hypertensive patients had a diastolic blood pressure equal to or more than 100 mg Hg just before beginning (TO) the active treatment period. Perindopril was then given as an oral once-daily dosage of 2 mg, this dosage having been determined in previous pharmacodynamic studies. 12 After 4 weeks, the dosage was increased to 4 mg once a day if the diastolic pressure was equal to or more than 95 mm Hg. After another 4-week treatment, the dosage was increased to 8 mg/day in resistant patients. Active treatment was stopped after a total of 12 weeks. At this time (T1), the active dose was 4 mg in eight patients, 8 mg in seven patients, and 2 mg in one patient. Thereafter, a second placebo period was instituted (4 weeks), and the study was stopped at this time (T2). Hemodynamic investigations were performed at TO, Tl, and T2; TO and T2 correspond to the two placebo periods and TI corresponds to the end of active treatment.
The hemodynamic study began at 9 AM during the day of hospitalization. It was carried out at a controlled room temperature of 20 + 0.50 C, the patients having rested for 30 being the angle used in the measurement. Once the arterial diameter was determined, the velocity of the whole arterial blood column was measured. For this, the width of the measurement volume was increased to the value of the arterial diameter. Its depth from the transducer was then adjusted so as to superimpose the measurement volume and the arterial lumen. The arterial blood velocity was expressed in centimeters per second, and mean arterial blood velocity was electronically integrated. Brachial artery blood flow was calculated as the product of blood velocity and cross-sectional area, the latter deduced from the arterial diameter (D) by a cylindrical representation of the artery (S = 3.14 D74). Arterial blood flow was expressed in milliliters per minute. Local vascular resistance (mm Hg/ml * sec) was cal- brachial artery was defined, according to LaPlace's law, as T = MAP x D/2 and was expressed in millimeters of mercury per centimeter. Immediately after the baseline determinations, the wrist was occluded for 5 minutes with a pneumatic cuff inflated to a suprasystolic pressure (250 mm Hg). Arterial diameter and blood flow velocity were rapidly measured again up to 5 minutes. No significant change in systemic blood pressure or heart rate was observed during the period of occlusion.
The variability of the Doppler measurements was studied in six subjects (independently of the 16 patients in the present study). After For the determination of brachio-radial pulse wave velocity (PWV), two pulse transducer heads (Electronics for Medicine) were fixed to the skin over the most prominent parts of the right brachial and radial arteries. The time delay was measured between the feet of simultaneously recorded pulse waves, with a paper speed of 150 mm/sec. The foot, which contains the high-frequency information,8 was defined as the point obtained by extrapolating the wave front downward and measured from the intersection of this line with a straight line extrapolation of the last part of the diastolic curve. 17 Measurement of the distance between the two transducers was then used to calculate pulse wave velocity. This was averaged over at least one respiration cycle of about 10 beats.
In primates, changes in pulse wave velocity have been shown to be very good indicators of arterial stiffness both under baseline conditions and after administration of vasoactive substances.8,17-24 In the present study, the variability of the method was studied by measuring pulse wave velocity before and after placebo in both short-term and long-term situations. In the former, measurements were performed at 9 and 12 AM, the placebo being administered at 9:15 AM in 11 healthy volunteers.25 MAP and pulse wave velocity did not change significantly, their respective preplacebo and postplacebo values being 83 +2 and 85 + 2 mm Hg and 9.7 +0.5 and 9.1 ± 0.5 m/sec, respectively. A similar study was performed in seven hypertensive patients before and after 4 weeks of administration of placebo (personal data). MAP before and after placebo was 123±4 and 121 ±4 mm Hg (NS), and pulse wave velocity was 12.6 ± 1.2 and 12.2 ± 1.4 m/sec (NS).
For the determination of brachial artery compliance, the equation of Bramwell and Hilll8 was used according to the following formula:
where V is arterial volume, dV is the change in volume, dP is the change in pressure, and p is the blood density. From this equation, it is easy to calculate brachial arterial compliance (BAC) as BAC = dV/dP = V/pPWV2 because V can be expressed in terms of radius per unit length: dV/dP= 3.14R2/pPWV2 where R is the inner radius of the artery (D/2). In this equation, dV/dP is expressed in centimeters to the fourth power per dyne times 10 Figure 3 summarizes the changes in arterial diameter and blood flow velocity produced by wrist occlusion. Although the decrease in blood flow velocity was significantly higher at TI than at TO or T2 (p<0.001), the reduction in arterial diameter was similar for all three periods. 15 On the other hand, our study of short-term and longterm variability has shown a 2.2% approximation of measurements, a finding that agrees with the significant changes in arterial diameter produced by antihypertensive agents in long-term double-blind studies. 6, 7, 32 In contrast with arterial diameter, the variability of blood flow velocity was greater, although its measurement is easier and more accurate. This peculiarity is attributable to the well-known rapidity of changes in cutaneous blood flow and to the rich innervation of the hand,31 favoring instantaneous modifications in blood flow velocity. Finally, comparisons of the variability of arterial diameter and flow velocity strongly suggest that compliance determinations are even more reproducible than blood flow determinations in the forearm. 6, 7, 32 As far as echocardiographic parameters are concerned, numerous studies have documented sources of error derived from intraobserver and interobserver variability and interstudy reproducibility. 30 The absolute reductions in left ventricular wall thickness from which calculated cardiac mass changes are derived are usually 1-2 mm. This is close to the limit of variability attributable to measurement errors. 30, 33 diograms in eight subjects (r = 0.98; SD = 28 g) and readings of 24 echocardiograms by two experienced investigators (r= 0.94; SD = 41 g). These results were found to be strikingly similar to the mean difference of 26 g observed between measurements on echocardiograms performed more than a year apart in 53 normal subjects.M They are also smaller than the standard deviation of 43 g obtained in a comparison of echocardiographic and necropsy measurements. 27 In the present study, the long-term follow-up that we have performed without any treatment (see "Patients and Methods") agrees with these findings. On the other hand, the changes observed with perindopril (TO) and after the treatment was stopped (T2) accord with the results of studies in which serial changes in a control group receiving a placebo were compared with changes in the treatment group. 35 Finally, the differential responses in cardiac and arterial parameters are influenced not only by the sensitivity and reliability of each technique but also by the relative sensitivity of the two techniques when used together in long-term follow-up. The main problem with both techniques is the positioning of the transducer. For echocardiographic measurements, the wall thicknesses and chamber dimensions used should reflect the true minor axis as closely as possible to prevent tangential displays of the wall and the left ventricular chamber.30 For Doppler measurements, the problem is to determine exactly the angle between the ultrasound beam and the vessel axis. In this regard, it is clear that the Doppler technique enables a very precise mathematical evaluation of the angle, as previously reported.15 Indeed, with the double transducer probe used in this study, the reproducibility of the measurement angle is less than 2%.15
Increase in Brachial Artery Diameter
With single-blind design versus placebo, the study clearly showed that the converting enzyme inhibitor perindopril causes an increase in brachial artery diam- 38 Evidence is accumulating that this dilatation is dependent on the endothelium. 39 Removal of the endothelium in isolated perfused canine coronary or femoral arteries in situ is able to abolish the flow-dependent dilatation. 36, 39 In the case of the converting enzyme inhibitor perindopril, the possible role of the endothelium must be carefully considered because endothelial cells contain large amounts of converting enzyme and may be a privileged site of action of converting enzyme inhibitors. 40 On the other hand, the brachial artery dilatation attributable to converting enyzme inhibition may be influenced by bradykinin release, the mechanism of which is endothelium dependent. 41, 42 In the present study, the role of flow-dependent dilatation was evaluated from the hemodynamic effects of wrist occlusion at suprasystolic blood pressure level. The manoeuver consistently resulted in significant reduction in diameter, blood flow velocity, and volumic blood flow at each period of the study (TO, TI, and T2). These changes may have been attributed to a direct or reflexly mediated rise in local vascular resistance. After perindopril (T1), the significant increase in blood flow velocity, observed under basal conditions, was no longer observed during wrist occlusion. This finding suggests either that the vasodilator effect of perindopril was predominantly attributable to relaxation of hand arteries or that a reflex vasoconstriction of small forearm arteries in response to wrist occlusion might have compensated for the vasodilator effect of perindopril. The increase in brachial artery diameter in response to perindopril was significant at TI. However, the increase did not occur during wrist occlusion (Figure 3) . Several explanations may be suggested. First, the mechanism of the relaxation of large arteries after perindopril may have been flowdependent because it no longer occurred when the increase in blood flow velocity was suppressed. 43 However, this is probably not the only mechanism, as the converting enzyme inhibitor captopril has been shown to increase the caliber of the common carotid artery without any significant increase in blood flow velocity in hypertensive subjects.44 Second, the lack of any significant increase in brachial artery diameter during wrist occlusion could have been attributable to the small number of patients or, third, to the counteracting effect of a reflexly mediated vasoconstriction in response to venous dilatation45 or an arousal stimulus46 on inflation of the wrist cuff.
An alternative explanation to flow-dependent dilatation for the increased brachial artery diameter is smooth muscle relaxation.9 Studies in healthy volunteers have shown that increasing doses of perindopril (causing a 90% decrease in plasma converting enzyme) produced changes in brachial and carotid arterial diameters only at the highest doses.47 This suggests that the drug affects large arteries by mechanisms other than the simple inhibition of circulating converting enzyme. Local modifications of the vascular tissue may be related not only to converting enzyme inhibition but also to the role of prostaglandin release and/ or kinin accumulation and, finally, inhibition of the sympathetic nervous system.48
Increase in Brachial Artery Compliance
After perindopril administration, not only the caliber of the brachial artery was expected to be modified but also the viscoelastic properties of its wall and, hence, its distensibility. According to the Moens-Korteweg and Bramwell and Hill equations,8'18 pulse wave velocity reflects the distensibility characteristics of large arteries, which, in turn, determine vascular impedance (or total opposition to pulsatile flow). The distensibility of arteries depends on several factors, such as the elastic modulus of the arterial wall, the geometry of the vessel (i.e., its diameter and thickness), and the extent to which the arterial wall is stretched (i.e., transmural pressure).49 All of these factors should be evaluated when the distensibility changes of arteries are being investigated. The brachioradial pulse wave velocity decreased significantly after perindopril, whereas brachial artery diameter increased and the distending pressure decreased. As the arterial wall thickness (assumed to be relatively thin) is supposed to vary inversely with radius (i.e., to become thinner when arterial diameter increases849), the geometric and mechanical modifications of the brachial artery need to be taken into account in explaining the compliance enhancement after perindopril. Table 1 terior wall thickness. However, 4 weeks after the treatment was stopped, cardiac mass remained low, whereas blood pressure and arterial compliance had returned toward baseline values. As mentioned above, the present findings may be influenced by the relative sensitivity of the two techniques used to study the cardiac and arterial changes. Because the accuracy of our noninvasive hemodynamic measurements largely agrees with wellestablished long-term studies, hypotheses other than technical problems may be advanced. The finding that cardiac mass remained low 4 weeks after cessation of active treatment does not mean that it will not return toward baseline values later. In this regard, our findings suggest only that the time constant for reversal of cardiac and arterial changes may be different in hypertensive patients after cessation of active treatment. Because reversal of structural changes was indeed observed in the heart after perindopril, one possibility is that structural changes may be different in the heart and vessels. Studies in hypertensive animals have shown that captopril causes minimal changes in aortic structure, whereas cardiac hypertrophy is reduced.10 The finding is consistent with the observation that in several animal models of hypertension, significant increases in collagen biosynthesis and total collagen content are observed in the larger arteries.50,5' In contrast, the collagen concentration often remains essentially unchanged, especially in treated animals.50 '5' In conclusion, the present study has shown that in patients with sustained essential hypertension, the converting enzyme inhibitor perindopril increases brachial artery diameter and compliance through drugmediated modifications of the arterial wall, these being largely unrelated to the blood pressure modifications. The arterial changes seemed mainly to affect smooth muscle activity and were dissociated from cardiac effects after the treatment was stopped.
